Monday, October 3, 2022


Biotechnology News Magazine

Zylorion Announces Filing of 2 U.S. Provisional Patent Applications Related to Novel Psilocybin-Based Compounds

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

PsiloTec Health Solutions Inc., operating as Zylorion Health, (“Zylorion” or the “Company”), a mental health care and psychedelic therapy focused innovator, announced today the filing of two separate provisional patent applications with the United States Patent and Trademark Office (“USPTO”) related to the Company’s novel psilocybin-based drug product candidates, ZYL-312 and ZYL-314.

These two provisional patent applications establish an effective date for the priority and protection of the unique composition of Zylorion’s novel psilocybin-based drug product compounds. The provisional patents describe the novel composition of the compounds and therapeutic uses for the treatment of certain mental health and central nervous system disorders.

“As we continue to advance our intellectual property strategy and build out a portfolio of assets, this is an important milestone in the development of our novel treatment approaches that will integrate Zylorion’s proprietary therapy program with its novel drug product candidates. These filings will help facilitate our clinical programs that focus on key areas of high unmet need in mental health,” commented Dr. Peter Silverstone, Chief Executive Officer & Director.

Zylorion’s proprietary multi-modal therapy program incorporates biosensors, virtual reality, and other sensory related therapies, and is designed to work in conjunction with psychedelic-based drug compounds. A scalable digital platform facilitates a blended-therapy approach with the ability to capture longitudinal data and enhanced through artificial intelligence (AI) to deliver superior outcomes and improved treatment protocols.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine